Alves, Christiano R. R. http://orcid.org/0000-0002-2646-9689
Ha, Leillani L.
Yaworski, Rebecca
Sutton, Emma R.
Lazzarotto, Cicera R. http://orcid.org/0000-0003-1093-0175
Christie, Kathleen A.
Reilly, Aoife
Beauvais, Ariane
Doll, Roman M. http://orcid.org/0000-0003-3991-6043
de la Cruz, Demitri
Maguire, Casey A.
Swoboda, Kathryn J. http://orcid.org/0000-0002-4593-6342
Tsai, Shengdar Q. http://orcid.org/0000-0001-9161-3993
Kothary, Rashmi http://orcid.org/0000-0002-9239-7310
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Article History
Received: 21 January 2023
Accepted: 12 October 2023
First Online: 6 December 2023
Competing interests
: C.R.R.A., K.A.C., K.J.S. and B.P.K. are inventors on a patent application filed by Mass General Brigham (MGB) that describes genome engineering technologies to treat SMA. S.Q.T. and C.R.L are co-inventors on a patent application describing the CHANGE-seq method. S.Q.T. is a member of the scientific advisory board of Kromatid, Twelve Bio and Prime Medicine. C.A.M. has a financial interest in Sphere Gene Therapeutics, Chameleon Biosciences and Skylark Bio, companies developing gene therapy platforms. C.A.M.’s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies. C.A.M. has a filed patent application with claims involving the AAV-F capsid. B.P.K. is an inventor on additional patents or patent applications filed by MGB that describe genome engineering technologies. B.P.K. is a consultant for EcoR1 capital and is on the scientific advisory board of Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. S.Q.T. and B.P.K. have financial interests in Prime Medicine, a company developing therapeutic CRISPR–Cas technologies for gene editing. B.P.K.‘s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies. The other authors declare no competing interests.